UPDATE: Dougherty Downgrades Hologic; Lowers PT

Loading...
Loading...
According to a research report published this morning, Dougherty has downgraded Hologic
HOLX
to Neutral, and lowered PT from $26 to $20. In the report, Dougherty commented, "Hologic reported F2Q:12 sales of $471.2MM (vs. our $473.0MM; Street $474.0MM) and EPS of $0.33 (vs. our $0.34; Street $0.33)—we note that the Breast Health business was surprisingly weaker than expected at $218.6MM (vs. our $225.4MM; Street $222.0MM). We would have expected a healthier Breast Health business, given the Dimensions Tomosynthesis Year-2 rollout. Ultimately, we ponder whether the Gen-Probe transaction is a smoke-screen for a weaker base business." Hologic closed yesterday at $19.11.
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorDowngradesPrice TargetAnalyst RatingsDougherty
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...